PATENT CLAIM ANALYSIS

Application Number: 16055659
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["424", "139100"]

Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Claim (Index 48):
The method of  claim 46 , wherein the disorder comprises neurological diseases selected from the group consisting of dementia, senile dementia, mild cognitive impairment, Alzheimer-related dementia, Huntington's chorea, tardive dyskinesia, hyperkinesias, manias, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis, glaucoma and Alzheimer's disease.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.6875
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11943770', '14989532', '14013916', '11983775', '12693940']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7842540536899276
- 35 USC 102 Novelty (BERT): 0.5565286857248629
- Combined Prediction Score: 0.7614815168934211
- Mean Citation Score: 391.015772
- Max Citation Score: 460.20157
- Similarity Product: 283.39959842805507

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test